An alpha-glucosidase inhibitor may be used as monotherapy for patients with type 2 diabetes that is inadequately controlled by non pharmacological measures. because alpha-glucosidase inhibitors target postprandial hyperflycaemia, they can be a useful first-line treatment in patients who hap a combination of only slightly raised basal glucose concentrations and more marked postprandial hyperglycemia.